Sign Up to like & get recommendations! 1
Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.15072
Abstract: Key Points Question What is the risk of developing cardiomyopathy among patients with the acute phase of Chagas infection or the indeterminate chronic form of Chagas disease? Findings In this systematic review and meta-analysis of… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25252
Abstract: globulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients. Leukemia. 2018. https://doi.org/10.1038/ s41375-018-0194-x 3. Kohlhagen MC, Barnidge DR, Mills JR, et al. Screening method for M-proteins in serum… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5762
Abstract: Avascular necrosis (AVN) of bone is a debilitating complication of pediatric patients with acute lymphoblastic leukemia (ALL). While it is extensively studied and reported in Western population, studies focused on Orientals are limited. This study… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5858
Abstract: In older patients with acute myeloid leukemia (AML), the definition of fitness, prognosis, and risk of death represents an open question. read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.26918
Abstract: Implantation of early‐generation metallic drug‐eluting stents (DES) in patients with acute myocardial infarction (AMI) is associated with poor vessel wall healing. Use of biodegradable polymer (BP) DES might improve safety outcomes; however, the impact of… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.28369
Abstract: Stroke represents a potentially calamitous complication among patients with acute coronary syndrome (ACS) undergoing percutaneous intervention (PCI). Data on the distribution of stroke occurrence post‐PCI and its impact on mortality are scarce. read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.28653
Abstract: To investigate the optimal dual antiplatelet therapy (DAPT) duration for diabetic patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.30025
Abstract: The aim of this study was to analyze the feasibility of a physiological coronary evaluation with the instantaneous wave‐free ratio (iFR) of nonculprit lesions in patients with acute coronary syndrome (ACS) successfully revascularized. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.30077
Abstract: To evaluate the effectiveness and safety of ticagrelor versus clopidogrel in patients with acute coronary syndromes (ACS) undergoing complex percutaneous coronary intervention (PCI). read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.30467
Abstract: The American Heart Association/American College of Cardiology guidelines on dual antiplatelet therapy (DAPT) recommend at least 12 months of a P2Y12 inhibitor and low dose aspirin in patients with an acute coronary syndrome (ACS) treated… read more here.
Sign Up to like & get recommendations! 1
Published in 2017 at "Clinical Cardiology"
DOI: 10.1002/clc.22823
Abstract: In patients with acute pulmonary embolism (PE), detectable levels of cardiac troponin I (cTnI) using a highly sensitive assay have been associated with increased in‐hospital mortality. We sought to investigate the impact of detectable cTnI… read more here.